^
Association details:
Biomarker:BRAF V600E
Cancer:Melanoma
Drug:PHI-501 (pan-RAF inhibitor, DDR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

411 / 6 - PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma

Published date:
03/15/2023
Excerpt:
PHI-501 demonstrated potent growth inhibition (GI50 <1 µM) in seven melanoma cell lines harboring BRAF V600E or NRAS mutations….PHI-501 triggered apoptosis more effectively than these inhibitors...PHI-501 had 74-fold more inhibitory effect on cell proliferation (GI50: 0.55 µM to 40 µM). Moreover, treatment with PHI-501 strongly suppressed cell migration of cobimetinib-resistant SK-MEL-30 cells.